U.S. Markets close in 1 hr 20 mins

Blog Coverage Dr. Reddy's Labs Launches Generic Osteoporosis Drug Tablets in the US

LONDON, UK / ACCESSWIRE / November 14, 2016 / Active Wall St. blog coverage looks at the headline from Dr. Reddy's Laboratories Ltd (NYSE: RDY) as the company announced on November 11, 2016, that it had launched a generic Osteoporosis drug, raloxifene hydrochloride, in tablet form in the US. The tablet is a therapeutic equivalent of Eli Lilly and Co. (NYSE: LLY)'s tablet Evista. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

Today, AWS is promoting its blog coverage on RDY and LLY. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=RDY

http://www.activewallst.com/registration-3/?symbol=LLY

Dr. Reddy's generic version has received necessary approvals from the US Food & Drug Administration (FDA) and has been launched in bottle count sizes of 30, 100 and 1,000 tablets of 60 mg each. Evista and other generic versions of the tablet generate a sale of $265 million MAT as per IMS Health.
Dr. Reddy's is an Indian integrated pharmaceuticals company and operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The pharmaceuticals company manufactures, markets, and/or distributes more than 100 drugs in the US. In 2006, US drug giant Merck has signed a pact with Dr Reddy's Labs to sell two of its products in the US. The first drug was the generic version of cholesterol reducing drug Simvastatin, branded as Zocor, and the second drug was Finasteride, or Proscar, which is used to treat patients with prostate hyperplasia. Furthering the partnership, Dr. Reddy's in June 2012, had signed a research pact with Merck's Serono biopharmaceutical division for jointly developing copies of complex biotechnology drugs.

About Evista (raloxifene hydrochloride)

Evista is a prescription drug, an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. It is a proprietary product of Eli Lilly and Company. It is prescribed to women only after menopause. It has various uses including for the treatment and prevention of osteoporosis. It is also prescribed to patients at high risk for breast cancer as it lowers the chances of getting invasive breast cancer. The tablet is to be taken orally daily and the recommended dosage is one 60 mg tablet per day.

Generics

The first Evista generic was launched by Teva Pharmaceuticals USA, Inc. in April 2014. Other companies which have launched the Evista therapeutic equivalent and are being sold in the US markets are: Amneal Pharms', Aurobindo Pharma Ltd, Watson Labs Inc., Invagen Pharms, Glenmark Pharma Ltd. All of them have received the necessary approvals from US FDA for their products.

Stock Performance

Last Friday, Dr. Reddy's Labs' stock closed the trading session at $48.52, slipping by 1.48% from its previous closing price of $49.25. A total volume of 387.03 thousand shares have exchanged hands, which was higher than the 3-month average volume of 251.36 thousand shares. The company's stock price advanced 5.89% in the last month, 8.04% in the past three months, and 8.42% in the previous six months. The stock has a market capital of $8.34 billion.

At the closing bell, on Friday, November 11, 2016, Eli Lilly's stock marginally fell by 0.86%, ending the trading session at $77.67. A total volume of 3.07 million shares were traded at the end of the day. In the last six months, shares of the company have advanced 0.49%. The company's shares are trading at a PE ratio of 33.73 and have a dividend yield of 2.63%. The stock has a market capital of $85.80 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street